Development and validation of a new stability indicating liquid chromatographic method for the simultaneous quantification of hydrochlorthiazide and telmisartan

Telmisartan is an angiotensin receptor blocker and Hydrochlorothiazide is used to treat edema caused by various heart, kidney and liver diseases. Telmisartan is used in combination with a thiazide-type diuretic such as Hydrochlorothiazide by which an additive blood pressure lowering effect was proved. A new stability indicating liquid chromatographic method has been developed for the simultaneous estimation of Telmisartan and Hydrochlorthiazide in tablets. Chromatographic separation was achieved by using a X Bridge shield RP C-18 (150mm × 3.0mm, 3.5μm) column of Waters HPLC with Empower2 software and PDA detector, maintained at 45 ºC. Gradient mode of elution was performed and the flow rate of the mobile phase was 0.8 mL/min (Detector wavelength 235nm). Forced degradation studies were performed and the proposed method was found to be selective and specific